SOPHiA GENETICS (NASDAQ:SOPH) Insider Philippe Menu Sells 5,000 Shares

Posted by Stanley Muller on Jun 3rd, 2026

SOPHiA GENETICS SA (NASDAQ:SOPH – Get Free Report) insider Philippe Menu sold 5,000 shares of the company’s stock in a transaction that occurred on Tuesday, May 26th. The stock was sold at an average price of $4.95, for a total value of $24,750.00. Following the sale, the insider owned 250,780 shares of the company’s stock, valued at $1,241,361. This trade represents a 1.95% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Philippe Menu also recently made the following trade(s):

On Monday, April 27th, Philippe Menu sold 5,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.82, for a total value of $24,100.00.
On Monday, April 20th, Philippe Menu sold 608 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.20, for a total value of $3,161.60.
On Tuesday, April 14th, Philippe Menu sold 1,600 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.96, for a total value of $7,936.00.
On Monday, April 13th, Philippe Menu sold 4,400 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.76, for a total value of $20,944.00.
On Friday, April 10th, Philippe Menu sold 3,725 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.68, for a total value of $17,433.00.
On Thursday, April 9th, Philippe Menu sold 1,931 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.74, for a total value of $9,152.94.
On Wednesday, April 8th, Philippe Menu sold 2,800 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.84, for a total value of $13,552.00.
On Tuesday, April 7th, Philippe Menu sold 2,400 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.87, for a total value of $11,688.00.
On Monday, April 6th, Philippe Menu sold 2,700 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.85, for a total value of $13,095.00.
On Thursday, March 19th, Philippe Menu sold 608 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.79, for a total value of $2,912.32.

SOPHiA GENETICS Stock Down 1.2%

SOPH opened at $4.99 on Tuesday. The company has a debt-to-equity ratio of 1.05, a current ratio of 2.06 and a quick ratio of 1.90. The business has a 50 day simple moving average of $4.95 and a 200-day simple moving average of $4.84. The stock has a market capitalization of $341.77 million, a P/E ratio of -9.60 and a beta of 0.98. SOPHiA GENETICS SA has a 12 month low of $2.59 and a 12 month high of $5.70.

SOPHiA GENETICS (NASDAQ:SOPH – Get Free Report) last posted its quarterly earnings results on Tuesday, May 5th. The company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.23) by ($0.04). The business had revenue of $21.69 million during the quarter, compared to analyst estimates of $20.40 million. SOPHiA GENETICS had a negative net margin of 44.48% and a negative return on equity of 62.74%.

Wall Street Analysts Forecast Growth

SOPH has been the subject of several research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of SOPHiA GENETICS in a report on Tuesday, April 21st. BTIG Research reaffirmed a “buy” rating and set a $8.00 price objective on shares of SOPHiA GENETICS in a report on Wednesday, May 6th. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $7.50.

View Our Latest Research Report on SOPH

Institutional Investors Weigh In On SOPHiA GENETICS

A number of hedge funds and other institutional investors have recently made changes to their positions in SOPH. Savvy Advisors Inc. purchased a new stake in shares of SOPHiA GENETICS in the third quarter valued at $48,000. Perkins Capital Management Inc. purchased a new stake in shares of SOPHiA GENETICS in the fourth quarter valued at $49,000. Squarepoint Ops LLC purchased a new stake in shares of SOPHiA GENETICS in the third quarter valued at $49,000. First Dallas Securities Inc. purchased a new stake in shares of SOPHiA GENETICS in the first quarter valued at $50,000. Finally, Quadrature Capital Ltd purchased a new stake in shares of SOPHiA GENETICS in the fourth quarter valued at $54,000. Hedge funds and other institutional investors own 31.59% of the company’s stock.

About SOPHiA GENETICS

(Get Free Report)

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.